MedTrace Logo

Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease

NCT04886063 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 423

Last updated 2025-04-01

Study results available
· View outcomes & findings →

Summary

The objective of this study is to determine the safety and tolerability of fosgonimeton (ATH-1017) in subjects with mild to moderate Alzheimer's disease who completed the 26-week randomized treatment in Study ATH-1017-AD-0201 or Study ATH-1017-AD-0202.

Conditions

  • Alzheimer Disease

Interventions

DRUG

ATH-1017

Daily subcutaneous (SC) injection of ATH-1017 in a pre-filled syringe

Sponsors & Collaborators

  • Athira Pharma

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
55 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-30
Primary Completion
2024-10-23
Completion
2024-10-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04886063 on ClinicalTrials.gov